{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:51:21Z","timestamp":1787017881386,"version":"build-2736575974"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"2","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":124,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["2133\/23"],"award-info":[{"award-number":["2133\/23"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019180","name":"HORIZON EUROPE European Research Council","doi-asserted-by":"publisher","award":["101094980"],"award-info":[{"award-number":["101094980"]}],"id":[{"id":"10.13039\/100019180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001698","name":"Israel Cancer Research Fund","doi-asserted-by":"publisher","award":["20 to 802-ICG"],"award-info":[{"award-number":["20 to 802-ICG"]}],"id":[{"id":"10.13039\/100001698","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","award":["917324"],"award-info":[{"award-number":["917324"]}],"id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["2569\/24"],"award-info":[{"award-number":["2569\/24"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>New approaches that generate long-lasting therapeutic responses in patients with therapy-resistant metastatic cancer are urgently needed. To address this challenge, we developed Spot Neoantigens in Metastases (SpotNeoMet), a novel data-driven pipeline that systematically identifies recurrently presented neopeptides in treatment-resistant patients. We identified seven therapy resistance mutations predicted to produce neopeptides presented by common HLAs. Using HLA immunopeptidomics, we discovered three novel neopeptides derived from androgen receptor (AR) H875Y, a common metastatic castration-resistant prostate cancer (mCRPC) mutation. We validated these neoantigens as highly immunogenic and then isolated and characterized cognate T-cell receptors (TCR) from healthy donor peripheral blood mononuclear cells. We demonstrated that AR H875Y\u2013specific TCRs are highly specific and kill prostate cancer cells presenting AR neopeptides in vitro and in vivo. Our new pipeline identifies novel immunotherapy targets and potential treatment options for patients with mCRPC. Moreover, SpotNeoMet offers a systematic route to identify \u201cHLA\u2013peptide\u201d pairs and their cognate TCRs across treatment-resistant cancers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>As the emergence of resistance to targeted treatments in patients with metastatic cancer, there is an urgent need for innovative therapeutic approaches for this population. Our study provides a new analytic framework to identify neoantigens from treatment-resistant mutations and a proof-of-concept T cell\u2013based immunotherapy treatment for mCRPC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2159-8290.cd-24-1213","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T19:39:06Z","timestamp":1759865946000},"page":"250-269","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer"],"prefix":"10.1158","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5589-6008","authenticated-orcid":false,"given":"Nofar","family":"Gumpert","sequence":"first","affiliation":[{"name":"1Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7234-0256","authenticated-orcid":false,"given":"Shira","family":"Sagie","sequence":"additional","affiliation":[{"name":"1Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel."},{"name":"2Jusidman Cancer Center, Sheba Medical Center, Ramat Gan, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2037-8487","authenticated-orcid":false,"given":"Claudia","family":"Arnedo-Pac","sequence":"additional","affiliation":[{"name":"3Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain."},{"name":"4Centro de Investigaci\u00f3n Biom\u00e9dica en Red en C\u00e1ncer, Instituto de Salud Carlos III, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1492-8036","authenticated-orcid":false,"given":"Tomer","family":"Babu","sequence":"additional","affiliation":[{"name":"1Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7772-7475","authenticated-orcid":false,"given":"Chen","family":"Weller","sequence":"additional","affiliation":[{"name":"1Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8582-4660","authenticated-orcid":false,"given":"Abel","family":"Gonzalez-Perez","sequence":"additional","affiliation":[{"name":"3Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain."},{"name":"4Centro de Investigaci\u00f3n Biom\u00e9dica en Red en C\u00e1ncer, Instituto de Salud Carlos III, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7750-3587","authenticated-orcid":false,"given":"Yuan","family":"Wang","sequence":"additional","affiliation":[{"name":"5Department of Computer Science, Princeton University, Princeton, New Jersey."},{"name":"6Lewis-Sigler Institute of Integrative Genomics, Princeton University, Princeton, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2098-4302","authenticated-orcid":false,"given":"Lucas","family":"Michel Tod\u00f3","sequence":"additional","affiliation":[{"name":"7Systems Oncology Program, Vall d\u2019Hebron Institute of Oncology (VHIO), Vall d\u2019Hebron Barcelona Hospital Campus, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9574-2132","authenticated-orcid":false,"given":"Ronen","family":"Levy","sequence":"additional","affiliation":[{"name":"1Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3782-9029","authenticated-orcid":false,"given":"Xi","family":"Chen","sequence":"additional","affiliation":[{"name":"5Department of Computer Science, Princeton University, Princeton, New Jersey."},{"name":"6Lewis-Sigler Institute of Integrative Genomics, Princeton University, Princeton, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3459-0766","authenticated-orcid":false,"given":"Polina","family":"Greenberg","sequence":"additional","affiliation":[{"name":"1Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3278-3510","authenticated-orcid":false,"given":"Maria","family":"Dayan-Rubinov","sequence":"additional","affiliation":[{"name":"1Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3030-6385","authenticated-orcid":false,"given":"Elizabeta","family":"Yakubovich","sequence":"additional","affiliation":[{"name":"1Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6693-8819","authenticated-orcid":false,"given":"Talya","family":"Wasserman-Bartov","sequence":"additional","affiliation":[{"name":"1Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4074-1344","authenticated-orcid":false,"given":"Mirie","family":"Zerbib","sequence":"additional","affiliation":[{"name":"8Department of Veterinary Resources, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3910-9260","authenticated-orcid":false,"given":"Jianhui","family":"Gong","sequence":"additional","affiliation":[{"name":"9Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5532-581X","authenticated-orcid":false,"given":"Ryan J.","family":"Rebernick","sequence":"additional","affiliation":[{"name":"9Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6872-1311","authenticated-orcid":false,"given":"Anna","family":"Oliveira Tercero","sequence":"additional","affiliation":[{"name":"10Department of Medical Oncology and Prostate Cancer Translational Research Group, Vall d\u2019Hebron Institute of Oncology (VHIO) and Vall d\u2019Hebron University Hospital, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4499-7395","authenticated-orcid":false,"given":"Laura","family":"Agundez Muriel","sequence":"additional","affiliation":[{"name":"10Department of Medical Oncology and Prostate Cancer Translational Research Group, Vall d\u2019Hebron Institute of Oncology (VHIO) and Vall d\u2019Hebron University Hospital, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3761-9467","authenticated-orcid":false,"given":"Gil","family":"Benedek","sequence":"additional","affiliation":[{"name":"11Tissue Typing and Immunogenetics Unit, Hadassah Medical Center, Jerusalem, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3289-8818","authenticated-orcid":false,"given":"Merav","family":"Kedmi","sequence":"additional","affiliation":[{"name":"12Department of Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1228-412X","authenticated-orcid":false,"given":"Roni","family":"Oren","sequence":"additional","affiliation":[{"name":"8Department of Veterinary Resources, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9604-1939","authenticated-orcid":false,"given":"Shifra","family":"Ben-Dor","sequence":"additional","affiliation":[{"name":"13Bioinformatics Unit, Department of Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7279-0246","authenticated-orcid":false,"given":"Yishai","family":"Levin","sequence":"additional","affiliation":[{"name":"14The de Botton Institute for Protein Profiling, The Nancy and Stephen Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5676-5737","authenticated-orcid":false,"given":"Olga G.","family":"Troyanskaya","sequence":"additional","affiliation":[{"name":"5Department of Computer Science, Princeton University, Princeton, New Jersey."},{"name":"6Lewis-Sigler Institute of Integrative Genomics, Princeton University, Princeton, New Jersey."},{"name":"15Center for Computational Biology, Flatiron Institute, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5639-5027","authenticated-orcid":false,"given":"Asl\u0131 D.","family":"Munzur","sequence":"additional","affiliation":[{"name":"16Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2399-0329","authenticated-orcid":false,"given":"Alexander W.","family":"Wyatt","sequence":"additional","affiliation":[{"name":"16Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada."},{"name":"17Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5467-1040","authenticated-orcid":false,"given":"Marcin P.","family":"Cieslik","sequence":"additional","affiliation":[{"name":"18Department of Pathology, University of Michigan, Ann Arbor, Michigan."},{"name":"19Department of Computational Medicine and Bioinformatics, Ann Arbor, Michigan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4726-1473","authenticated-orcid":false,"given":"David A.","family":"Quigley","sequence":"additional","affiliation":[{"name":"20Department of Urology, UCSF, San Francisco, California."},{"name":"21Department of Epidemiology & Biostatistics, UCSF, San Francisco, California."},{"name":"22Helen Diller Family Comprehensive Cancer Center, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0201-4444","authenticated-orcid":false,"given":"Eliezer M.","family":"Van Allen","sequence":"additional","affiliation":[{"name":"23Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"24Cancer Program, Broad Institute of MIT and Harvard, Boston, Massachusetts."},{"name":"25Parker Institute for Cancer Immunotherapy, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0473-8358","authenticated-orcid":false,"given":"Niroshana","family":"Anandasabapathy","sequence":"additional","affiliation":[{"name":"26Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, Meyer Cancer Center, Englander Institute for Precision Medicine and Department of Dermatology, Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5336-2548","authenticated-orcid":false,"given":"Joaquin","family":"Mateo","sequence":"additional","affiliation":[{"name":"10Department of Medical Oncology and Prostate Cancer Translational Research Group, Vall d\u2019Hebron Institute of Oncology (VHIO) and Vall d\u2019Hebron University Hospital, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1755-1349","authenticated-orcid":false,"given":"Xinbo","family":"Yang","sequence":"additional","affiliation":[{"name":"27Molecular Pharmacology Program, Sloan Kettering Institute Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7804-1134","authenticated-orcid":false,"given":"Francisco","family":"Mart\u00ednez-Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"7Systems Oncology Program, Vall d\u2019Hebron Institute of Oncology (VHIO), Vall d\u2019Hebron Barcelona Hospital Campus, Barcelona, Spain."},{"name":"28Hartwig Medical Foundation, Amsterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4925-8988","authenticated-orcid":false,"given":"Nuria","family":"Lopez-Bigas","sequence":"additional","affiliation":[{"name":"3Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain."},{"name":"4Centro de Investigaci\u00f3n Biom\u00e9dica en Red en C\u00e1ncer, Instituto de Salud Carlos III, Madrid, Spain."},{"name":"7Systems Oncology Program, Vall d\u2019Hebron Institute of Oncology (VHIO), Vall d\u2019Hebron Barcelona Hospital Campus, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3349-7266","authenticated-orcid":false,"given":"Yardena","family":"Samuels","sequence":"additional","affiliation":[{"name":"1Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"2026020910290812100_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"2026020910290812100_bib2","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"key":"2026020910290812100_bib3","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.3390\/ijms23052847","article-title":"Challenges of the immunotherapy: perspectives and limitations of the immune checkpoint inhibitor treatment","volume":"23","author":"Dobosz","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026020910290812100_bib4","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s43018-023-00588-x","article-title":"The landscape of T cell antigens for cancer immunotherapy","volume":"4","author":"Peri","year":"2023","journal-title":"Nat Cancer"},{"key":"2026020910290812100_bib5","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"2026020910290812100_bib6","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/s41587-023-01945-y","article-title":"Systematic discovery of neoepitope-HLA pairs for neoantigens shared among patients and tumor types","volume":"42","author":"Gurung","year":"2024","journal-title":"Nat Biotechnol"},{"key":"2026020910290812100_bib7","doi-asserted-by":"crossref","first-page":"e129466","DOI":"10.1172\/JCI129466","article-title":"Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma","volume":"131","author":"Peri","year":"2021","journal-title":"J Clin Invest"},{"key":"2026020910290812100_bib8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s44320-023-00001-w","article-title":"Hotspot propensity across mutational processes","volume":"20","author":"Arnedo-Pac","year":"2024","journal-title":"Mol Syst Biol"},{"key":"2026020910290812100_bib9","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41586-019-1689-y","article-title":"Pan-cancer whole-genome analyses of metastatic solid tumours","volume":"575","author":"Priestley","year":"2019","journal-title":"Nature"},{"key":"2026020910290812100_bib10","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.cell.2018.02.060","article-title":"Comprehensive characterization of cancer driver genes and mutations","volume":"173","author":"Bailey","year":"2018","journal-title":"Cell"},{"key":"2026020910290812100_bib11","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41586-021-03771-1","article-title":"In silico saturation mutagenesis of cancer genes","volume":"596","author":"Mui\u00f1os","year":"2021","journal-title":"Nature"},{"key":"2026020910290812100_bib12","doi-asserted-by":"crossref","first-page":"D436","DOI":"10.1093\/nar\/gkae1092","article-title":"The immune epitope database (IEDB): 2024 update","volume":"53","author":"Vita","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"2026020910290812100_bib13","doi-asserted-by":"crossref","first-page":"W458","DOI":"10.1093\/nar\/gkx248","article-title":"GibbsCluster: unsupervised clustering and alignment of peptide sequences","volume":"45","author":"Andreatta","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"2026020910290812100_bib14","doi-asserted-by":"crossref","first-page":"D428","DOI":"10.1093\/nar\/gkac965","article-title":"The MHC Motif Atlas: a database of MHC binding specificities and ligands","volume":"51","author":"Tadros","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"2026020910290812100_bib15","doi-asserted-by":"crossref","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","article-title":"NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data","volume":"48","author":"Reynisson","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"2026020910290812100_bib16","doi-asserted-by":"crossref","first-page":"100519","DOI":"10.1016\/j.mcpro.2023.100519","article-title":"Large-scale immunopeptidome analysis reveals recurrent posttranslational splicing of cancer- and immune-associated genes","volume":"22","author":"Levy","year":"2023","journal-title":"Mol Cell Proteomics"},{"key":"2026020910290812100_bib17","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.3389\/fimmu.2019.02731","article-title":"Analysis of secondary structure biases in naturally presented HLA-I ligands","volume":"10","author":"Perez","year":"2019","journal-title":"Front Immunol"},{"key":"2026020910290812100_bib18","doi-asserted-by":"crossref","first-page":"e002071","DOI":"10.1136\/jitc-2020-002071","article-title":"HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy","volume":"9","author":"Marcu","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026020910290812100_bib19","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1038\/s41596-019-0170-6","article-title":"Induction of neoantigen-reactive T cells from healthy donors","volume":"14","author":"Ali","year":"2019","journal-title":"Nat Protoc"},{"key":"2026020910290812100_bib20","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026020910290812100_bib21","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.cell.2018.06.039","article-title":"Genomic hallmarks and structural variation in metastatic prostate cancer","volume":"174","author":"Quigley","year":"2018","journal-title":"Cell"},{"key":"2026020910290812100_bib22","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41586-022-04975-9","article-title":"Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer","volume":"608","author":"Herberts","year":"2022","journal-title":"Nature"},{"key":"2026020910290812100_bib23","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1158\/2326-6066.CIR-18-0686","article-title":"Immunologic recognition of a shared p53 mutated neoantigen in a patient with metastatic colorectal cancer","volume":"7","author":"Lo","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"2026020910290812100_bib24","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/CJI.0000000000000453","article-title":"A novel cell-based Luciferase reporter platform for the development and characterization of T-cell redirecting therapies and vaccine development","volume":"46","author":"Grailer","year":"2023","journal-title":"J Immunother"},{"key":"2026020910290812100_bib25","doi-asserted-by":"crossref","first-page":"e003001","DOI":"10.1136\/jitc-2021-003001","article-title":"Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies","volume":"9","author":"Lo","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026020910290812100_bib26","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1001\/jamaoncol.2016.0494","article-title":"Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer","volume":"2","author":"Wyatt","year":"2016","journal-title":"JAMA Oncol"},{"key":"2026020910290812100_bib27","doi-asserted-by":"crossref","first-page":"883989","DOI":"10.3389\/fimmu.2022.883989","article-title":"The importance of being presented: target validation by immunopeptidomics for epitope-specific immunotherapies","volume":"13","author":"Becker","year":"2022","journal-title":"Front Immunol"},{"key":"2026020910290812100_bib28","doi-asserted-by":"crossref","first-page":"100045","DOI":"10.1016\/j.immuno.2024.100045","article-title":"Lessons learned from the IMMREP23 TCR-epitope prediction challenge","volume":"16","author":"Nielsen","year":"2024","journal-title":"ImmunoInformatics"},{"key":"2026020910290812100_bib29","doi-asserted-by":"crossref","first-page":"851868","DOI":"10.3389\/fimmu.2022.851868","article-title":"Public T-cell receptors (TCRs) revisited by analysis of the magnitude of identical and highly-similar TCRs in virus-specific T-cell repertoires of healthy individuals","volume":"13","author":"Huisman","year":"2022","journal-title":"Front Immunol"},{"key":"2026020910290812100_bib30","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1200\/JCO.23.00233","article-title":"Pembrolizumab Plus Olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: the randomized, open-label, phase III KEYLYNK-010 trial","volume":"41","author":"Antonarakis","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026020910290812100_bib31","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"2026020910290812100_bib32","doi-asserted-by":"crossref","first-page":"1181051","DOI":"10.3389\/fimmu.2023.1181051","article-title":"Efficacy and safety of immune checkpoint inhibitors for patients with prostate cancer: a systematic review and meta-analysis","volume":"14","author":"Noori","year":"2023","journal-title":"Front Immunol"},{"key":"2026020910290812100_bib33","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-024-02979-8","article-title":"PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"30","author":"Dorff","year":"2024","journal-title":"Nat Med"},{"key":"2026020910290812100_bib34","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1158\/1078-0432.CCR-23-2978","article-title":"A phase I study of Acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer","volume":"30","author":"Dorff","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026020910290812100_bib35","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1158\/2326-6066.CIR-24-0119","article-title":"TCR-based therapy directed against Kallikrein-related peptidase 4 is safe and effective against prostate cancer","volume":"13","author":"van Amerongen","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"2026020910290812100_bib36","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/s41586-022-04522-6","article-title":"Androgen receptor activity in T cells limits checkpoint blockade efficacy","volume":"606","author":"Guan","year":"2022","journal-title":"Nature"},{"key":"2026020910290812100_bib37","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat Protoc"},{"key":"2026020910290812100_bib38","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41586-023-06054-z","article-title":"Pan-cancer whole-genome comparison of primary and metastatic solid tumours","volume":"618","author":"Mart\u00ednez-Jim\u00e9nez","year":"2023","journal-title":"Nature"},{"key":"2026020910290812100_bib39","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41568-020-0290-x","article-title":"A compendium of mutational cancer driver genes","volume":"20","author":"Mart\u00ednez-Jim\u00e9nez","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"2026020910290812100_bib40","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cels.2020.06.010","article-title":"MHCflurry 2.0: improved pan-allele prediction of MHC class I-presented peptides by incorporating antigen processing","volume":"11","author":"O'Donnell","year":"2020","journal-title":"Cell Syst"},{"key":"2026020910290812100_bib41","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1158\/2326-6066.CIR-19-0464","article-title":"High-throughput prediction of MHC class I and II neoantigens with MHCnuggets","volume":"8","author":"Shao","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"2026020910290812100_bib42","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41588-023-01367-1","article-title":"Genetic immune escape landscape in primary and metastatic cancer","volume":"55","author":"Mart\u00ednez-Jim\u00e9nez","year":"2023","journal-title":"Nat Genet"},{"key":"2026020910290812100_bib43","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/nmeth.2642","article-title":"IntOGen-mutations identifies cancer drivers across tumor types","volume":"10","author":"Gonzalez-Perez","year":"2013","journal-title":"Nat Methods"},{"key":"2026020910290812100_bib44","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/ng.2653","article-title":"The genotype-tissue expression (GTEx) project","volume":"45","author":"GTEx Consortium","year":"2013","journal-title":"Nat Genet"},{"key":"2026020910290812100_bib45","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/nbt.1511","article-title":"MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification","volume":"26","author":"Cox","year":"2008","journal-title":"Nat Biotechnol"},{"key":"2026020910290812100_bib46","doi-asserted-by":"crossref","first-page":"9967","DOI":"10.1073\/pnas.1511996112","article-title":"Generation of MANAbodies specific to HLA-restricted epitopes encoded by somatically mutated genes","volume":"112","author":"Skora","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026020910290812100_bib47","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41586-023-06331-x","article-title":"A common allele of HLA is associated with asymptomatic SARS-CoV-2 infection","volume":"620","author":"Augusto","year":"2023","journal-title":"Nature"},{"key":"2026020910290812100_bib48","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1084\/jem.20082136","article-title":"Natural micropolymorphism in human leukocyte antigens provides a basis for genetic control of antigen recognition","volume":"206","author":"Archbold","year":"2009","journal-title":"J Exp Med"},{"key":"2026020910290812100_bib49","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/pro.4","article-title":"Conformational changes within the HLA-A1:MAGE-A1 complex induced by binding of a recombinant antibody fragment with TCR-like specificity","volume":"18","author":"Kumar","year":"2009","journal-title":"Protein Sci"},{"key":"2026020910290812100_bib50","doi-asserted-by":"crossref","first-page":"23900","DOI":"10.1074\/jbc.M503060200","article-title":"High resolution structures of highly bulged viral epitopes bound to major histocompatibility complex class I. Implications for T-cell receptor engagement and T-cell immunodominance","volume":"280","author":"Tynan","year":"2005","journal-title":"J Biol Chem"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/doi\/10.1158\/2159-8290.CD-24-1213\/3658749\/cd-24-1213.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/doi\/10.1158\/2159-8290.CD-24-1213\/3712273\/cd-24-1213.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/16\/2\/250\/3731673\/cd-24-1213.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/16\/2\/250\/3731673\/cd-24-1213.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T15:29:24Z","timestamp":1770650964000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/16\/2\/250\/772115\/Recurrent-Immunogenic-Neoantigens-and-Their"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,10,8]]},"published-print":{"date-parts":[[2026,2,6]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-24-1213","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2159-8290.31296519","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31296507","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31276692","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31296504","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31276680","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31296528","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31296516","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31276674","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31296522","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31296544","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31276662","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31296510","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31296489","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31276698","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31276686","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31296556","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31276701","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31276656","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31276644","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31296562","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31276713","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31296550","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31276668","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31296483","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31296559","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31296525","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31296547","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31276683","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31276671","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31276695","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31276641","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31296565","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31276665","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31296535","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31276653","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31296501","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31276677","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31276710","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31276647","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31296486","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31296498","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31296541","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31276716","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31276659","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31296492","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.31276704","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.c.8295309","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]}}}